Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Tao Tao, MD
- Phone Number: +86-13817701776
- Email: taotaozhen@hotmail.com
Study Locations
-
-
-
Shanghai, China, 200127
- Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PCOS of childbearing age (24-45 years old);
- non-obesity;
- After 6 months of metformin (at least 1000-1500 mg/d) intervention, the normal menstrual cycle was still not restored.
- No drug intervention except metformin was used in last 3 monthes:
- There is a pregnancy plan within 1 years.
- The pregnancy test was negative.
- Heart and liver function is normal, thyroid function is normal, adrenal function is normal.
- The GnRH stimulation test confirmed that the pituitary and ovarian reserve function was good.
- Chromosome examination is normal.
- Did not take part in other clinical trials.
Exclusion Criteria:
- PCOS was not diagnosed.
- Severe liver and kidney dysfunction (ALT is 2.5 times greater than normal upper limit, or Cr > 132 umol/l, or eGFR < 60 mL/min/1.73 m2), thyroid dysfunction, adrenal dysfunction, psychosis, severe infection, severe anemia, neutropenia;
- Other serious organic heart diseases, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, NYHA cardiac function grade (> III);
- Kallmann syndrome, secondary hypogonadotropic hypogonadism, acquired central nervous system diseases, infertility caused by hypothalamic amenorrhea and other secondary infertility;
- Has a history of abuse of active substances, including alcohol and a history of alcohol related diseases in the past 2 years.
- Previous history of central nervous system and gonad-related surgery, or other central nervous system and gonad-related surgery (such as central nervous system tumor resection, ovarian chocolate cyst resection) within one year, or other non-central nervous system and gonad surgery within six months;
- In the past five years, there have been organ system tumors (except for local cutaneous basal cell carcinomas) that have been treated or not treated, regardless of whether there is evidence of local recurrence or metastasis;
- Hypoglycemic drugs, contraceptives (Dain, Marvelon), ovulation-promoting drugs (clomiphene, letrozole), emergency contraceptives and sex hormone drugs have been or are being used to adjust menstrual cycle and promote ovulation except metformin.
- Pregnancy;
- GnRH stimulation test confirmed pituitary and ovarian reserve dysfunction.
- Abnormal chromosome detection.
- Patients who are allergic to drugs with similar chemical structure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pulsatile Gonadotropin-releasing Hormone
Drug: Gonadorelin.
Use Gonadorelin for 3 months to treat PCOS.
The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
|
Drug: Gonadotropin-releasing Hormone.
Generic name: Gonadorelin.
Dosage form: 600ug.
Dosage: 10ug/puls.
Frequency: every 90 min.
Duration: 3 months
|
|
Experimental: Clomiphene
Use Clomiphene for 3 months to treat PCOS
|
Drug: Clomiphene.
Generic name: Clomiphene.
Dosage form: 50mg.
Dosage: 50mg.
Frequency: once a day.
Duration: 3 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with ovulation recovery (according to basal body temperature, progesterone levels on cycle day 21, or ultrasonography)
Time Frame: up to 12 weeks
|
Number of participants with ovulation recovery (according to basal body temperature, progesterone levels on cycle day 21, or ultrasonography) after use of drugs
|
up to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: up to 12 weeks
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
Evaluation of efficacy and safety of short-term GnRH pulse therapy for non obese PCOS
|
up to 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: TAO TAO, DM, Renji Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Syndrome
- Infertility
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Clomiphene
- Prolactin Release-Inhibiting Factors
Other Study ID Numbers
Other Study ID Numbers
- 18411968700
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.